André, P., Denis, C., Soulas, C., Bourbon-Caillet, C., Lopez, J., Arnoux, T., . . . Vivier, E. (2018). Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK Cells. Cell, 175(7), 1731-1743.e1713. doi:10.1016/j.cell.2018.10.014
AWH, C., J, Z., S, B., H, T., A, C., K, S., . . . PJ, J. (2018). Development of pre and post-operative models to predict early recurrence of hepatocellular carcinoma after surgical resection. Journal of hepatology, 69(6), 1284-1293. doi:10.1016/j.jhep.2018.08.027
Bins, S., Basak, E. A., El Bouazzaoui, S., Koolen, S. L. W., Oomen-de Hoop, E., van der Leest, C. H., . . . Mathijssen, R. H. J. (2018). Association between single-nucleotide polymorphisms and adverse events in nivolumab-treated non-small cell lung cancer patients. Br J Cancer, 118(10), 1296-1301. doi:10.1038/s41416-018-0074-1
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 68(6), 394-424. doi:10.3322/caac.21492
Budczies, J., Allgäuer, M., Litchfield, K., Rempel, E., Christopoulos, P., Kazdal, D., . . . Stenzinger, A. (2019). Optimizing panel-based tumor mutational burden (TMB) measurement. Ann Oncol, 30(9), 1496-1506. doi:10.1093/annonc/mdz205
Chan, T. A., Yarchoan, M., Jaffee, E., Swanton, C., Quezada, S. A., Stenzinger, A., & Peters, S. (2019). Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic. Ann Oncol, 30(1), 44-56. doi:10.1093/annonc/mdy495
Chen, P. H., Cai, L., Huffman, K., Yang, C., Kim, J., Faubert, B., . . . DeBerardinis, R. J. (2019). Metabolic Diversity in Human Non-Small Cell Lung Cancer Cells. Mol Cell, 76(5), 838-851.e835. doi:10.1016/j.molcel.2019.08.028
Chhabra, Y., Wong, H. Y., Nikolajsen, L. F., Steinocher, H., Papadopulos, A., Tunny, K. A., . . . Waters, M. J. (2018). A growth hormone receptor SNP promotes lung cancer by impairment of SOCS2-mediated degradation. Oncogene, 37(4), 489-501. doi:10.1038/onc.2017.352
Cristescu, R., Mogg, R., Ayers, M., Albright, A., Murphy, E., Yearley, J., . . . Kaufman, D. (2018). Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy. Science, 362(6411). doi:10.1126/science.aar3593
Cronin, K. A., Lake, A. J., Scott, S., Sherman, R. L., Noone, A. M., Howlader, N., . . . Jemal, A. (2018). Annual Report to the Nation on the Status of Cancer, part I: National cancer statistics. Cancer, 124(13), 2785-2800. doi:10.1002/cncr.31551
Fridman, W. H., Pagès, F., Sautès-Fridman, C., & Galon, J. (2012). The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer, 12(4), 298-306. doi:10.1038/nrc3245
Goodman, A. M., Kato, S., Bazhenova, L., Patel, S. P., Frampton, G. M., Miller, V., . . . Kurzrock, R. (2017). Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers. Mol Cancer Ther, 16(11), 2598-2608. doi:10.1158/1535-7163.mct-17-0386
Goodman, A. M., Piccioni, D., Kato, S., Boichard, A., Wang, H. Y., Frampton, G., . . . Kurzrock, R. (2018). Prevalence of PDL1 Amplification and Preliminary Response to Immune Checkpoint Blockade in Solid Tumors. JAMA Oncol, 4(9), 1237-1244. doi:10.1001/jamaoncol.2018.1701
Guo, J., Jin, H., Xi, Y., Guo, J., Jin, Y., & Jiang, D. (2020). The miR-582/CD1B Axis Is Involved in Regulation of Dendritic Cells and Is Associated with Clinical Outcomes in Advanced Lung Adenocarcinoma. Biomed Res Int, 2020, 4360930. doi:10.1155/2020/4360930
Hajian-Tilaki, K. (2013). Receiver Operating Characteristic (ROC) Curve Analysis for Medical Diagnostic Test Evaluation. Caspian J Intern Med, 4(2), 627-635.
Heagerty, P. J., Lumley, T., & Pepe, M. S. (2000). Time-dependent ROC curves for censored survival data and a diagnostic marker. Biometrics, 56(2), 337-344. doi:10.1111/j.0006-341x.2000.00337.x
Hellmann, M. D., Nathanson, T., Rizvi, H., Creelan, B. C., Sanchez-Vega, F., Ahuja, A., . . . Wolchok, J. D. (2018). Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer. Cancer Cell, 33(5), 843-852.e844. doi:10.1016/j.ccell.2018.03.018
Hsu, Y. C., Chang, Y. H., Chang, G. C., Ho, B. C., Yuan, S. S., Li, Y. C., . . . Chen, H. Y. (2019). Tumor mutation burden and recurrent tumors in hereditary lung cancer. Cancer Med, 8(5), 2179-2187. doi:10.1002/cam4.2120
Inamura, K. (2018). Clinicopathological Characteristics and Mutations Driving Development of Early Lung Adenocarcinoma: Tumor Initiation and Progression. Int J Mol Sci, 19(4). doi:10.3390/ijms19041259
Kim, S., Schaubel, D. E., & McCullough, K. P. (2018). A C-index for recurrent event data: Application to hospitalizations among dialysis patients. Biometrics, 74(2), 734-743. doi:10.1111/biom.12761
Krop, I., Parker, M. T., Bloushtain-Qimron, N., Porter, D., Gelman, R., Sasaki, H., . . . Polyak, K. (2005). HIN-1, an inhibitor of cell growth, invasion, and AKT activation. Cancer Res, 65(21), 9659-9669. doi:10.1158/0008-5472.can-05-1663
Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., . . . Diaz, L. A., Jr. (2017). Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science, 357(6349), 409-413. doi:10.1126/science.aan6733
Liu, M., Zhou, S., Wang, J., Zhang, Q., Yang, S., Feng, J., . . . Zhong, S. (2019). Identification of genes associated with survival of breast cancer patients. Breast Cancer, 26(3), 317-325. doi:10.1007/s12282-018-0926-9
Lv, C., & Huang, L. (2020). Xenobiotic receptors in mediating the effect of sepsis on drug metabolism. Acta Pharm Sin B, 10(1), 33-41. doi:10.1016/j.apsb.2019.12.003
Marchetti, A., Barassi, F., Martella, C., Chella, A., Salvatore, S., Castrataro, A., . . . Buttitta, F. (2004). Down regulation of high in normal-1 (HIN-1) is a frequent event in stage I non-small cell lung cancer and correlates with poor clinical outcome. Clin Cancer Res, 10(4), 1338-1343. doi:10.1158/1078-0432.ccr-1174-03
Maung, T. Z., Ergin, H. E., Javed, M., Inga, E. E., & Khan, S. (2020). Immune Checkpoint Inhibitors in Lung Cancer: Role of Biomarkers and Combination Therapies. Cureus, 12(5), e8095. doi:10.7759/cureus.8095
Mayakonda, A., Lin, D. C., Assenov, Y., Plass, C., & Koeffler, H. P. (2018). Maftools: efficient and comprehensive analysis of somatic variants in cancer. Genome Res, 28(11), 1747-1756. doi:10.1101/gr.239244.118
Mazumdar, J., Hickey, M. M., Pant, D. K., Durham, A. C., Sweet-Cordero, A., Vachani, A., . . . Keith, B. (2010). HIF-2alpha deletion promotes Kras-driven lung tumor development. Proc Natl Acad Sci U S A, 107(32), 14182-14187. doi:10.1073/pnas.1001296107
Melosky, B., Juergens, R., McLeod, D., Leighl, N., Brade, A., Card, P. B., & Chu, Q. (2019). Immune checkpoint-inhibitors and chemoradiation in stage III unresectable non-small cell lung cancer. Lung Cancer, 134, 259-267. doi:10.1016/j.lungcan.2019.05.027
Middha, S., Zhang, L., Nafa, K., Jayakumaran, G., Wong, D., Kim, H. R., . . . Hechtman, J. F. (2017). Reliable Pan-Cancer Microsatellite Instability Assessment by Using Targeted Next-Generation Sequencing Data. JCO Precis Oncol, 2017. doi:10.1200/po.17.00084
Montuno, M. A., Kohner, A. B., Foote, K. D., & Okun, M. S. (2013). An algorithm for management of deep brain stimulation battery replacements: devising a web-based battery estimator and clinical symptom approach. Neuromodulation, 16(2), 147-153. doi:10.1111/j.1525-1403.2012.00457.x
Nanavaty, P., Alvarez, M. S., & Alberts, W. M. (2014). Lung cancer screening: advantages, controversies, and applications. Cancer Control, 21(1), 9-14. doi:10.1177/107327481402100102
Newman, A. M., Liu, C. L., Green, M. R., Gentles, A. J., Feng, W., Xu, Y., . . . Alizadeh, A. A. (2015). Robust enumeration of cell subsets from tissue expression profiles. Nat Methods, 12(5), 453-457. doi:10.1038/nmeth.3337
Newman, A. M., Steen, C. B., Liu, C. L., Gentles, A. J., Chaudhuri, A. A., Scherer, F., . . . Alizadeh, A. A. (2019). Determining cell type abundance and expression from bulk tissues with digital cytometry. Nat Biotechnol, 37(7), 773-782. doi:10.1038/s41587-019-0114-2
Pathan, M., Keerthikumar, S., Ang, C. S., Gangoda, L., Quek, C. Y., Williamson, N. A., . . . Mathivanan, S. (2015). FunRich: An open access standalone functional enrichment and interaction network analysis tool. Proteomics, 15(15), 2597-2601. doi:10.1002/pmic.201400515
Pereira, C. S., Pérez-Cabezas, B., Ribeiro, H., Maia, M. L., Cardoso, M. T., Dias, A. F., . . . Macedo, M. F. (2019). Lipid Antigen Presentation by CD1b and CD1d in Lysosomal Storage Disease Patients. Front Immunol, 10, 1264. doi:10.3389/fimmu.2019.01264
Remon, J., Vilariño, N., & Reguart, N. (2018). Immune checkpoint inhibitors in non-small cell lung cancer (NSCLC): Approaches on special subgroups and unresolved burning questions. Cancer Treat Rev, 64, 21-29. doi:10.1016/j.ctrv.2018.02.002
Ritchie, M. E., Phipson, B., Wu, D., Hu, Y., Law, C. W., Shi, W., & Smyth, G. K. (2015). limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res, 43(7), e47. doi:10.1093/nar/gkv007
Samstein, R. M., Lee, C. H., Shoushtari, A. N., Hellmann, M. D., Shen, R., Janjigian, Y. Y., . . . Morris, L. G. T. (2019). Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nat Genet, 51(2), 202-206. doi:10.1038/s41588-018-0312-8
Sangodkar, J., Katz, S., Melville, H., & Narla, G. (2010). Lung adenocarcinoma: lessons in translation from bench to bedside. Mt Sinai J Med, 77(6), 597-605. doi:10.1002/msj.20226
Shang, J., Song, Q., Yang, Z., Li, D., Chen, W., Luo, L., . . . Li, S. (2017). Identification of lung adenocarcinoma specific dysregulated genes with diagnostic and prognostic value across 27 TCGA cancer types. Oncotarget, 8(50), 87292-87306. doi:10.18632/oncotarget.19823
Shen, Y., Peng, X., & Shen, C. (2020). Identification and validation of immune-related lncRNA prognostic signature for breast cancer. Genomics, 112(3), 2640-2646. doi:10.1016/j.ygeno.2020.02.015
Steuer, C. E., & Ramalingam, S. S. (2018). Tumor Mutation Burden: Leading Immunotherapy to the Era of Precision Medicine? J Clin Oncol, 36(7), 631-632. doi:10.1200/jco.2017.76.8770
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., . . . Sznol, M. (2012). Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med, 366(26), 2443-2454. doi:10.1056/NEJMoa1200690
Torre, L. A., Bray, F., Siegel, R. L., Ferlay, J., Lortet-Tieulent, J., & Jemal, A. (2015). Global cancer statistics, 2012. CA Cancer J Clin, 65(2), 87-108. doi:10.3322/caac.21262
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J., Robert, L., . . . Ribas, A. (2014). PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature, 515(7528), 568-571. doi:10.1038/nature13954
van den Ende, T., van den Boorn, H. G., Hoonhout, N. M., van Etten-Jamaludin, F. S., Meijer, S. L., Derks, S., . . . van Laarhoven, H. W. M. (2020). Priming the tumor immune microenvironment with chemo(radio)therapy: A systematic review across tumor types. Biochim Biophys Acta Rev Cancer, 1874(1), 188386. doi:10.1016/j.bbcan.2020.188386
van Hall, T., André, P., Horowitz, A., Ruan, D. F., Borst, L., Zerbib, R., . . . Vivier, E. (2019). Monalizumab: inhibiting the novel immune checkpoint NKG2A. J Immunother Cancer, 7(1), 263. doi:10.1186/s40425-019-0761-3
van Oest, R. (2019). A new coefficient of interrater agreement: The challenge of highly unequal category proportions. Psychol Methods, 24(4), 439-451. doi:10.1037/met0000183
Wang, S., Cowley, L. A., & Liu, X. S. (2019). Sex Differences in Cancer Immunotherapy Efficacy, Biomarkers, and Therapeutic Strategy. Molecules, 24(18). doi:10.3390/molecules24183214
Wang, S., Zhang, J., He, Z., Wu, K., & Liu, X. S. (2019). The predictive power of tumor mutational burden in lung cancer immunotherapy response is influenced by patients' sex. Int J Cancer, 145(10), 2840-2849. doi:10.1002/ijc.32327
Warne, R. T., & Burningham, C. (2019). Spearman's g found in 31 non-Western nations: Strong evidence that g is a universal phenomenon. Psychol Bull, 145(3), 237-272. doi:10.1037/bul0000184
Yi, M., Nissley, D. V., McCormick, F., & Stephens, R. M. (2020). ssGSEA score-based Ras dependency indexes derived from gene expression data reveal potential Ras addiction mechanisms with possible clinical implications. Sci Rep, 10(1), 10258. doi:10.1038/s41598-020-66986-8
Yuan, J., Yuan, B., Zeng, L., Liu, B., Chen, Y., Meng, X., . . . Yang, S. (2020). Identification and validation of tumor microenvironment-related genes of prognostic value in lung adenocarcinoma. Oncol Lett, 20(2), 1772-1780. doi:10.3892/ol.2020.11735
Zehir, A., Benayed, R., Shah, R. H., Syed, A., Middha, S., Kim, H. R., . . . Berger, M. F. (2017). Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nat Med, 23(6), 703-713. doi:10.1038/nm.4333
Zhang, Y., Wang, D. C., Shi, L., Zhu, B., Min, Z., & Jin, J. (2017). Genome analyses identify the genetic modification of lung cancer subtypes. Semin Cancer Biol, 42, 20-30. doi:10.1016/j.semcancer.2016.11.005